VPS35 and Alzheimer disease: Importantly, our study represents a proof of principle for the druggability of VPS35 and supports the exciting possibility that, since this component of the recognition core can be targeted in vivo by pharmacological chaperone, it represents a novel and viable therapeutic approach against AD.